Gyurkocza Boglarka, Sandmaier Brenda M
Memorial Sloan Kettering Cancer Center, New York, NY; Weill Cornell Medical College of Cornell University, New York, NY;
Fred Hutchinson Cancer Research Center, Seattle, WA; and University of Washington School of Medicine, Seattle, WA.
Blood. 2014 Jul 17;124(3):344-53. doi: 10.1182/blood-2014-02-514778. Epub 2014 Jun 9.
An essential component of allogeneic and autologous hematopoietic cell transplantation (HCT) is the conditioning regimen administered before the hematopoietic cell infusion. Early regimens relied on dose intensity, assuming that high-dose chemoradiotherapy would eliminate malignant disease and reinfusion of the graft would then restore hematopoiesis. However, as the contribution of graft-versus-tumor effects to the success of allogeneic HCT was recognized over time, in an effort to exploit these, many investigators lowered the dose of radiation and chemotherapeutic agents in the preparative regimen. This resulted in a major paradigm shift, and consequently, the pool of eligible patients underwent a remarkable expansion. In this article, we provide a review of the definition of high-dose, reduced-intensity, and nonmyeloablative conditioning regimens, the most commonly used agents and combinations, and the evolution of some early regimens. We also provide a brief review of the toxicities associated with these regimens.
异基因和自体造血细胞移植(HCT)的一个重要组成部分是在造血细胞输注前给予的预处理方案。早期的方案依赖于剂量强度,认为高剂量放化疗能消除恶性疾病,然后移植的回输将恢复造血功能。然而,随着时间的推移,移植物抗肿瘤效应在异基因HCT成功中的作用得到认可,为了利用这些效应,许多研究者降低了预处理方案中放疗和化疗药物的剂量。这导致了一个重大的范式转变,因此,符合条件的患者群体显著扩大。在本文中,我们综述了高剂量、低强度和非清髓性预处理方案的定义、最常用的药物和组合,以及一些早期方案的演变。我们还简要综述了与这些方案相关的毒性。